{"id":"placebo-for-elagolix","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1208155","moleculeType":"Small molecule","molecularWeight":"631.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In Phase 3 trials for Elagolix, placebo serves as the comparator arm to demonstrate that observed clinical benefits are attributable to the active drug rather than natural disease progression or psychological factors.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:22.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials for Elagolix"}]},"trialDetails":[{"nctId":"NCT04333576","phase":"PHASE3","title":"Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-10","conditions":"Endometriosis","enrollment":800},{"nctId":"NCT06375811","phase":"PHASE3","title":"Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-03-16","conditions":"Infertility, Endometriosis","enrollment":297},{"nctId":"NCT03271489","phase":"PHASE3","title":"Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-13","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":478},{"nctId":"NCT06253702","phase":"PHASE4","title":"Brain Blood Flow Responses to Stress: Sex Differences","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2024-07-24","conditions":"Cerebrovascular Disorders","enrollment":22},{"nctId":"NCT04173169","phase":"PHASE3","title":"Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis","status":"COMPLETED","sponsor":"Yale University","startDate":"2022-03-15","conditions":"Infertility, Endometriosis","enrollment":103},{"nctId":"NCT06798571","phase":"PHASE4","title":"Role of Menopause in Thermoregulation","status":"RECRUITING","sponsor":"Penn State University","startDate":"2025-03-01","conditions":"Menopause, Aging","enrollment":24},{"nctId":"NCT03213457","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-07-07","conditions":"Endometriosis","enrollment":681},{"nctId":"NCT04614246","phase":"PHASE2","title":"Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb","status":"TERMINATED","sponsor":"Bayer","startDate":"2021-01-29","conditions":"Endometriosis","enrollment":215},{"nctId":"NCT05648669","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2022-09-04","conditions":"Endometriosis","enrollment":336},{"nctId":"NCT03886220","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-12","conditions":"Uterine Fibroids","enrollment":82},{"nctId":"NCT02925494","phase":"PHASE3","title":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-14","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":433},{"nctId":"NCT02691494","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-03","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":378},{"nctId":"NCT01441635","phase":"PHASE2","title":"Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":271},{"nctId":"NCT01817530","phase":"PHASE2","title":"Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":571},{"nctId":"NCT02654054","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-22","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":413},{"nctId":"NCT00437658","phase":"PHASE2","title":"Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2006-12-11","conditions":"Endometriosis","enrollment":252},{"nctId":"NCT00973973","phase":"PHASE2","title":"Efficacy and Safety Study of Elagolix in Women With Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-10-12","conditions":"Endometriosis, Pain","enrollment":137},{"nctId":"NCT01620528","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05-22","conditions":"Endometriosis","enrollment":872},{"nctId":"NCT00797225","phase":"PHASE2","title":"Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-11-26","conditions":"Endometriosis","enrollment":174},{"nctId":"NCT01931670","phase":"PHASE3","title":"A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-09-09","conditions":"Endometriosis","enrollment":815},{"nctId":"NCT00619866","phase":"PHASE2","title":"An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-02-19","conditions":"Endometriosis, Pain","enrollment":155}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Elagolix","genericName":"Placebo for Elagolix","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trials for Elagolix.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}